PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth above 1.5x AXSM's 8.89%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-121.69%
Negative operating income growth while AXSM is at 21.53%. Joel Greenblatt would press for urgent turnaround measures.
-139.60%
Negative net income growth while AXSM stands at 20.69%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-131.82%
Negative EPS growth while AXSM is at 20.78%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-131.82%
Negative diluted EPS growth while AXSM is at 20.78%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-31.70%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AXSM stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.37%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
75.95%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
7.00%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
81.58%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
47.75%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
-122.09%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-94.45%
Negative equity/share CAGR over 10 years while AXSM stands at 532.33%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
58.16%
Below 50% of AXSM's 119.36%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-73.50%
Negative 3Y equity/share growth while AXSM is at 183.86%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Negative asset growth while AXSM invests at 4.96%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-21.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.90%
We’re deleveraging while AXSM stands at 8.53%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
60.05%
We increase R&D while AXSM cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
231.77%
SG&A growth well above AXSM's 6.64%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.